ROMJ Fundamental Analysis - RUBICON ORGANICS INC

Fundamental Rating

ROMJ gets a fundamental rating of 6 out of 10. The analysis compared the fundamentals against 35 industry peers in the Pharmaceuticals industry. ROMJ has an excellent profitability rating, but there are some minor concerns on its financial health. ROMJ is growing strongly while it also seems undervalued. This is an interesting combination These ratings would make ROMJ suitable for value and growth investing!

Quickly go to:

1. Profitability

1.1 Basic Checks

In the past year ROMJ was profitable.
ROMJ had a positive operating cash flow in the past year.
In the past 5 years ROMJ always reported negative net income.
In multiple years ROMJ reported negative operating cash flow during the last 5 years.

1.2 Ratios

Looking at the Return On Assets, with a value of 4.93%, ROMJ belongs to the top of the industry, outperforming 82.86% of the companies in the same industry.
ROMJ has a Return On Equity of 7.01%. This is amongst the best in the industry. ROMJ outperforms 82.86% of its industry peers.
Looking at the Return On Invested Capital, with a value of 23.98%, ROMJ belongs to the top of the industry, outperforming 100.00% of the companies in the same industry.
Measured over the past 3 years, the Average Return On Invested Capital for ROMJ is significantly above the industry average of 8.45%.
The 3 year average ROIC (19.33%) for ROMJ is below the current ROIC(23.98%), indicating increased profibility in the last year.

		Industry Rank	Sector Rank
ROA	4.93%
ROE	7.01%
ROIC	23.98%

ROA(3y)-4.91%

ROA(5y)-14.11%

ROE(3y)-7.24%

ROE(5y)-22.2%

ROIC(3y)19.33%

ROIC(5y)N/A

1.3 Margins

With a decent Profit Margin value of 5.65%, ROMJ is doing good in the industry, outperforming 80.00% of the companies in the same industry.
ROMJ has a Operating Margin of 31.50%. This is amongst the best in the industry. ROMJ outperforms 100.00% of its industry peers.
ROMJ's Gross Margin of 64.91% is amongst the best of the industry. ROMJ outperforms 85.71% of its industry peers.
ROMJ's Gross Margin has improved in the last couple of years.

		Industry Rank	Sector Rank
OM	31.5%
PM (TTM)	5.65%
GM	64.91%

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3Y1.88%

GM growth 5YN/A

More info and screens

ROA

ROE

ROIC

Operating and Profit Margin

Show most profitable peers

2. Health

2.1 Basic Checks

With a Return on Invested Capital (ROIC) well above the Cost of Capital (WACC), ROMJ is creating value.
The number of shares outstanding for ROMJ has been increased compared to 1 year ago.
ROMJ has more shares outstanding than it did 5 years ago.
Compared to 1 year ago, ROMJ has an improved debt to assets ratio.

2.2 Solvency

ROMJ has an Altman-Z score of 1.82. This is not the best score and indicates that ROMJ is in the grey zone with still only limited risk for bankruptcy at the moment.
ROMJ has a Altman-Z score of 1.82. This is in the better half of the industry: ROMJ outperforms 80.00% of its industry peers.
ROMJ has a Debt/Equity ratio of 0.17. This is a healthy value indicating a solid balance between debt and equity.
ROMJ has a Debt to Equity ratio of 0.17. This is in the better half of the industry: ROMJ outperforms 65.71% of its industry peers.

		Industry Rank	Sector Rank
Debt/Equity	0.17
Debt/FCF	N/A
Altman-Z	1.82

ROIC/WACC2.6

WACC9.21%

2.3 Liquidity

A Current Ratio of 3.10 indicates that ROMJ has no problem at all paying its short term obligations.
With a decent Current ratio value of 3.10, ROMJ is doing good in the industry, outperforming 74.29% of the companies in the same industry.
ROMJ has a Quick Ratio of 1.33. This is a normal value and indicates that ROMJ is financially healthy and should not expect problems in meeting its short term obligations.
Looking at the Quick ratio, with a value of 1.33, ROMJ is in the better half of the industry, outperforming 62.86% of the companies in the same industry.

		Industry Rank	Sector Rank
Current Ratio	3.1
Quick Ratio	1.33

More info and screens

WACC

Debt/Equity

How to determine the health of a company

Altman-Z score

Show peers with great health

3. Growth

3.1 Past

ROMJ shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 228.33%, which is quite impressive.
ROMJ shows a strong growth in Revenue. In the last year, the Revenue has grown by 28.55%.
The Revenue has been growing by 29.14% on average over the past years. This is a very strong growth!

EPS 1Y (TTM)228.33%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%1475.86%

Revenue 1Y (TTM)28.55%

Revenue growth 3Y29.14%

Revenue growth 5YN/A

Sales Q2Q%15.77%

3.2 Future

The Earnings Per Share is expected to grow by 80.44% on average over the next years. This is a very strong growth
ROMJ is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 21.41% yearly.

EPS Next Y216.68%

EPS Next 2Y93.65%

EPS Next 3Y80.44%

EPS Next 5YN/A

Revenue Next Year21.78%

Revenue Next 2Y22.22%

Revenue Next 3Y21.41%

Revenue Next 5YN/A

3.3 Evolution

The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.

More info and screens

Find the best growth stocks

Show best growing peers

4. Valuation

4.1 Price/Earnings Ratio

A Price/Earnings ratio of 9.60 indicates a reasonable valuation of ROMJ.
Based on the Price/Earnings ratio, ROMJ is valued cheaply inside the industry as 82.86% of the companies are valued more expensively.
When comparing the Price/Earnings ratio of ROMJ to the average of the S&P500 Index (27.47), we can say ROMJ is valued rather cheaply.
With a Price/Forward Earnings ratio of 6.79, the valuation of ROMJ can be described as very cheap.
Based on the Price/Forward Earnings ratio, ROMJ is valued cheaply inside the industry as 85.71% of the companies are valued more expensively.
When comparing the Price/Forward Earnings ratio of ROMJ to the average of the S&P500 Index (24.26), we can say ROMJ is valued rather cheaply.

		Industry Rank	Sector Rank
PE	9.6
Fwd PE	6.79

4.2 Price Multiples

Compared to the rest of the industry, the Enterprise Value to EBITDA ratio of ROMJ indicates a rather cheap valuation: ROMJ is cheaper than 100.00% of the companies listed in the same industry.

		Industry Rank	Sector Rank
P/FCF	N/A
EV/EBITDA	1.66

4.3 Compensation for Growth

ROMJ's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
ROMJ has a very decent profitability rating, which may justify a higher PE ratio.
A more expensive valuation may be justified as ROMJ's earnings are expected to grow with 80.44% in the coming years.

PEG (NY)0.04

PEG (5Y)N/A

EPS Next 2Y93.65%

EPS Next 3Y80.44%

More info and screens

Show best valued peers

5. Dividend

5.1 Amount

ROMJ does not give a dividend.

		Industry Rank	Sector Rank
Dividend Yield	0%

More info and screens

Find the best dividend stocks

Show peers with best dividend

RUBICON ORGANICS INC

TSX-V:ROMJ (1/16/2026, 7:00:00 PM)

0.48

-0.01 (-1.03%)

Chartmill FA Rating

GICS SectorHealth Care

GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences

GICS IndustryPharmaceuticals

Earnings (Last)11-11 2025-11-11/amc

Earnings (Next)03-30 2026-03-30/amc

Inst Owners3.43%

Inst Owner ChangeN/A

Ins Owners42.68%

Ins Owner ChangeN/A

Market Cap32.25M

Revenue(TTM)57.19M

Net Income(TTM)3.23M

Analysts82.86

Price Target1.17 (143.75%)

Short Float %N/A

Short RatioN/A

Dividend

		Industry Rank	Sector Rank
Dividend Yield	0%

Yearly DividendN/A

Dividend Growth(5Y)N/A

DPN/A

Div Incr Years0

Div Non Decr Years0

Ex-DateN/A

Surprises & Revisions

EPS beat(2)1

Avg EPS beat(2)345.55%

Min EPS beat(2)-0.99%

Max EPS beat(2)692.08%

EPS beat(4)N/A

Avg EPS beat(4)N/A

Min EPS beat(4)N/A

Max EPS beat(4)N/A

EPS beat(8)N/A

Avg EPS beat(8)N/A

EPS beat(12)N/A

Avg EPS beat(12)N/A

EPS beat(16)N/A

Avg EPS beat(16)N/A

Revenue beat(2)1

Avg Revenue beat(2)7.42%

Min Revenue beat(2)-0.17%

Max Revenue beat(2)15.01%

Revenue beat(4)N/A

Avg Revenue beat(4)N/A

Min Revenue beat(4)N/A

Max Revenue beat(4)N/A

Revenue beat(8)N/A

Avg Revenue beat(8)N/A

Revenue beat(12)N/A

Avg Revenue beat(12)N/A

Revenue beat(16)N/A

Avg Revenue beat(16)N/A

PT rev (1m)0%

PT rev (3m)-11.54%

EPS NQ rev (1m)0%

EPS NQ rev (3m)N/A

EPS NY rev (1m)0%

EPS NY rev (3m)N/A

Revenue NQ rev (1m)0%

Revenue NQ rev (3m)-1.45%

Revenue NY rev (1m)0%

Revenue NY rev (3m)-0.84%

Valuation

		Industry Rank	Sector Rank
PE	9.6
Fwd PE	6.79
P/S	0.56
P/FCF	N/A
P/OCF	12.75
P/B	0.7
P/tB	0.74
EV/EBITDA	1.66

EPS(TTM)0.05

EY10.42%

EPS(NY)0.07

Fwd EY14.73%

FCF(TTM)-0.07

FCFYN/A

OCF(TTM)0.04

OCFY7.84%

SpS0.85

BVpS0.69

TBVpS0.65

PEG (NY)0.04

PEG (5Y)N/A

Graham Number0.88

Profitability

		Industry Rank	Sector Rank
ROA	4.93%
ROE	7.01%
ROCE	33.31%
ROIC	23.98%
ROICexc	27.36%
ROICexgc	28.81%
OM	31.5%
PM (TTM)	5.65%
GM	64.91%
FCFM	N/A

ROA(3y)-4.91%

ROA(5y)-14.11%

ROE(3y)-7.24%

ROE(5y)-22.2%

ROIC(3y)19.33%

ROIC(5y)N/A

ROICexc(3y)24.75%

ROICexc(5y)N/A

ROICexgc(3y)26.66%

ROICexgc(5y)N/A

ROCE(3y)26.85%

ROCE(5y)N/A

ROICexgc growth 3YN/A

ROICexgc growth 5YN/A

ROICexc growth 3YN/A

ROICexc growth 5YN/A

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3Y1.88%

GM growth 5YN/A

F-Score6

Asset Turnover0.87

Health

		Industry Rank	Sector Rank
Debt/Equity	0.17
Debt/FCF	N/A
Debt/EBITDA	0.37
Cap/Depr	212.76%
Cap/Sales	12.07%
Interest Coverage	20.97
Cash Conversion	11.9%
Profit Quality	N/A
Current Ratio	3.1
Quick Ratio	1.33
Altman-Z	1.82

F-Score6

WACC9.21%

ROIC/WACC2.6

Cap/Depr(3y)93.56%

Cap/Depr(5y)171.69%

Cap/Sales(3y)7.51%

Cap/Sales(5y)22.12%

Profit Quality(3y)N/A

Profit Quality(5y)N/A

High Growth Momentum

Growth

EPS 1Y (TTM)228.33%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%1475.86%

EPS Next Y216.68%

EPS Next 2Y93.65%

EPS Next 3Y80.44%

EPS Next 5YN/A

Revenue 1Y (TTM)28.55%

Revenue growth 3Y29.14%

Revenue growth 5YN/A

Sales Q2Q%15.77%

Revenue Next Year21.78%

Revenue Next 2Y22.22%

Revenue Next 3Y21.41%

Revenue Next 5YN/A

EBIT growth 1Y65.92%

EBIT growth 3YN/A

EBIT growth 5YN/A

EBIT Next Year-64.02%

EBIT Next 3Y-0.22%

EBIT Next 5YN/A

FCF growth 1Y-228.39%

FCF growth 3YN/A

FCF growth 5YN/A

OCF growth 1Y-62.76%

OCF growth 3YN/A

OCF growth 5YN/A

RUBICON ORGANICS INC / ROMJ.CA FAQ

What is the fundamental rating for ROMJ stock?

ChartMill assigns a fundamental rating of 6 / 10 to ROMJ.CA.

Can you provide the valuation status for RUBICON ORGANICS INC?

ChartMill assigns a valuation rating of 8 / 10 to RUBICON ORGANICS INC (ROMJ.CA). This can be considered as Undervalued.

Can you provide the profitability details for RUBICON ORGANICS INC?

RUBICON ORGANICS INC (ROMJ.CA) has a profitability rating of 7 / 10.

What is the financial health of RUBICON ORGANICS INC (ROMJ.CA) stock?

The financial health rating of RUBICON ORGANICS INC (ROMJ.CA) is 5 / 10.

What is the earnings growth outlook for RUBICON ORGANICS INC?

The Earnings per Share (EPS) of RUBICON ORGANICS INC (ROMJ.CA) is expected to grow by 216.68% in the next year.

RUBICON ORGANICS INC (ROMJ.CA) Stock Fundamental Analysis

1. Profitability

1.1 Basic Checks

1.2 Ratios

1.3 Margins

More info and screens

2. Health

2.1 Basic Checks

2.2 Solvency

2.3 Liquidity

More info and screens

3. Growth

3.1 Past

3.2 Future

3.3 Evolution

More info and screens

4. Valuation

4.1 Price/Earnings Ratio

4.2 Price Multiples

4.3 Compensation for Growth

More info and screens

5. Dividend

5.1 Amount

More info and screens

RUBICON ORGANICS INC / ROMJ.CA FAQ

What is the fundamental rating for ROMJ stock?

Can you provide the valuation status for RUBICON ORGANICS INC?

Can you provide the profitability details for RUBICON ORGANICS INC?

What is the financial health of RUBICON ORGANICS INC (ROMJ.CA) stock?

What is the earnings growth outlook for RUBICON ORGANICS INC?